Expert review of vaccines
-
Expert review of vaccines · May 2010
ReviewPopulation impact of Vi capsular polysaccharide vaccine.
Development of a safe and efficacious vaccine against typhoid fever has been the mainstay of enteric vaccinology since production of the first parenteral whole-cell typhoid vaccine in 1896. The new-generation Vi polysaccharide single-dose injectable typhoid vaccine developed in the 1980s is widely used in countries where it is locally produced, such as China, and in travelers from industrialized countries to typhoid-endemic settings. ⋯ Recent evidence of herd protection conferred by the Vi vaccine has highlighted the significance of the vaccine's effects beyond the vaccinated population. The large-scale use of this vaccine can yield protective benefits to a larger population and can reduce the epidemiologic and economic burden of typhoid fever in endemic countries.